Evaluation of Nudt15 -Guided Thiopurine Dose Individualization In Vivo Using CRISPR/Cas9-Edited Mouse Model
Takaya Moriyama(Mie University), Jun J. Yang(St. Jude Children's Research Hospital), Atushi Manabe(St. Luke's International Hospital), Kentaro Kihira(Mie University), Chase C. Suiter(University of Washington), Rina Nishii(Bristol-Myers Squibb (United States)), Katsuyoshi Koh(Saitama Children's Medical Center), Scott A. Brown(St. Jude Children's Research Hospital), Hiroki Hori(Mie University), Ting-Nien Lin(St. Jude Children's Research Hospital), Motohiro Kato(The University of Tokyo), Laura J. Janke(St. Jude Children's Research Hospital), Hidemi Toyoda(Mie University), Masatoshi Takagi(Tokyo Medical and Dental University), Ru Chen(Baylor College of Medicine), Lie Li(Qingdao University)
Cited by 0
Related Papers
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
|Nature Genetics|2016|473
Inherited <i>NUDT15</i> Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2015|443